NEUPRO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEUPRO (NEUPRO).
Rotigotine is a non-ergoline dopamine agonist with high affinity for dopamine D1, D2, D3, D4, and D5 receptors; also binds to serotonin 5-HT1A and alpha2-adrenergic receptors.
| Metabolism | Primarily hepatic via conjugation (sulfation and glucuronidation) and N-dealkylation; CYP450 enzymes play a minor role; no major active metabolites. |
| Excretion | Renal: 45% (metabolites), Fecal: 40% (metabolites), Biliary: 15% |
| Half-life | Single dose: 5-7 hours (transdermal); steady state: 7-10 hours; effective half-life for dosing is 8 hours due to reservoir in skin |
| Protein binding | 99.5% bound (primarily to albumin, also to alpha-1-acid glycoprotein) |
| Volume of Distribution | 370 L (≈5.3 L/kg for 70 kg); indicates extensive tissue distribution |
| Bioavailability | Transdermal: 20-80% (mean 45%) due to variable skin permeation; relative to IV: 45% |
| Onset of Action | Transdermal: 2-6 hours (clinical effect within 24 hours; steady state by day 2-3) |
| Duration of Action | 24 hours after single application; continuous delivery over 24 hours; once-daily application recommended |
Apply transdermally once daily; initial dose 2 mg/24h, titrated weekly by 2 mg/24h up to 6 mg/24h, maximum 8 mg/24h.
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | No dosage adjustment required for mild to moderate renal impairment (CrCl >=30 mL/min). Not recommended in severe renal impairment (CrCl <30 mL/min) or dialysis. |
| Liver impairment | No dosage adjustment required for mild hepatic impairment (Child-Pugh A). Use with caution in moderate hepatic impairment (Child-Pugh B); no established dose modification. Not recommended in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy not established in pediatric patients; off-label use not recommended. |
| Geriatric use | Initial dose 2 mg/24h; titrate slowly. Higher incidence of adverse effects (nausea, dizziness, hallucinations). Monitor renal function as age-related decline may alter clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NEUPRO (NEUPRO).
| Breastfeeding | Rotigotine is excreted in rat milk; unknown in human milk. M/P ratio not determined. Caution in nursing women due to potential for adverse effects in infants (e.g., somnolence, dystonia). |
| Teratogenic Risk | Pregnancy Category C. In animal studies, rotigotine caused fetal malformations at maternally toxic doses. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk. First trimester: limited data; second/third trimester: unknown risk of fetal harm. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to rotigotine or any component of the patch","Concomitant use with neuroleptic or antidopaminergic agents (relative)"]
| Precautions | ["Sudden onset of sleep during daily activities","Symptomatic hypotension (orthostatic hypotension)","Hallucinations and psychotic-like behavior","Impulse control disorders (e.g., pathological gambling, hypersexuality)","Fibrotic complications (e.g., pleural effusion, retroperitoneal fibrosis)","Melanoma risk (monitor skin lesions)","Application site reactions (skin patch)","Augmentation and rebound in RLS","Elevated blood pressure and heart rate"] |
Loading safety data…
| Fetal Monitoring |
| Monitor for excessive somnolence, hypotension, and impulse control disorders in the mother. Fetal monitoring: standard prenatal care, consider ultrasound for growth if prolonged use. |
| Fertility Effects | In animal studies, rotigotine reduced fertility at high doses. Clinical effects on human fertility unknown; may cause hyperprolactinemia via dopamine agonism, potentially impairing ovulation. |